Scholarlink

Purpose of Review <p>The current treatments for hormone receptor–positive (HR+) breast cancer (BC) have significantly improved patients’ overall survival rate and quality of life. Nonetheless, there exists a clear unmet need to explore novel strategies to enhance tumor response and overcome treatment resistance. Immune checkpoint inhibitors (ICI) represent a potential treatment option, and our review summarizes the emerging evidence on the outcomes of ICIs in HR + BC.</p> Recent Findings <p>A limited benefit has been observed from standalone ICI therapy in HR + BC, indicating that combinational strategies are necessary. The concurrent use of ICI with conventional chemotherapeutic agents has shown encouraging results and could be a frontrunner combination, particularly early in the disease course and in a selected patient population with an immune-enriched tumor microenvironment.&#xa0;</p> Summary <p>The potential of a practice-changing ICI-based regimen in HR+BC is a tangible goal that could soon be realized through the ongoing phase 3 trials. To extend the benefit to a larger patient population, future clinical studies are needed to investigate novel combinations of ICI with newer-generation endocrine therapies, cyclin-dependent kinase-targeting agents, or antibody drug conjugates.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Potential Role of Immunotherapy in ER-positive Breast Cancer

  • 期刊论文

  • 发表日期：

    2025年12月15日

查看全文
  • Faisal Fa’ak

摘要

Purpose of Review

The current treatments for hormone receptor–positive (HR+) breast cancer (BC) have significantly improved patients’ overall survival rate and quality of life. Nonetheless, there exists a clear unmet need to explore novel strategies to enhance tumor response and overcome treatment resistance. Immune checkpoint inhibitors (ICI) represent a potential treatment option, and our review summarizes the emerging evidence on the outcomes of ICIs in HR + BC.

Recent Findings

A limited benefit has been observed from standalone ICI therapy in HR + BC, indicating that combinational strategies are necessary. The concurrent use of ICI with conventional chemotherapeutic agents has shown encouraging results and could be a frontrunner combination, particularly early in the disease course and in a selected patient population with an immune-enriched tumor microenvironment. 

Summary

The potential of a practice-changing ICI-based regimen in HR+BC is a tangible goal that could soon be realized through the ongoing phase 3 trials. To extend the benefit to a larger patient population, future clinical studies are needed to investigate novel combinations of ICI with newer-generation endocrine therapies, cyclin-dependent kinase-targeting agents, or antibody drug conjugates.